Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Ozgecan Dulgar"'
Publikováno v:
European Journal of Breast Health, Vol 16, Iss 4, Pp 276-281 (2020)
Objective:Triple-negative-breast-cancer (TNBC) is a very heterogenous disease some of which are very aggressive and have poor prognosis. No targeted therapy is available. Immune response and tumor-infiltrating lymphocytes (TIL) can be related to long
Externí odkaz:
https://doaj.org/article/7804ae5a81cf4f3e9cc97010c30584b1
Autor:
Wei Wang, Andrew Haydon, Rebecca Johnson, Elisabeth Livingstone, Zeynep Eroglu, Grant A McArthur, Douglas B Johnson, Prachi Bhave, Georgina Long, Adnan Khattak, Matteo S Carlino, Johanna Mangana, Katharina Kahler, Angela Hong, Serigne N Lo, Hui-Ling Yeoh, Alexander Maxwell Menzies, Ozgecan Dulgar, Georg C Lodde, Axel Hausschild
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss 3 (2023)
Background In patients with stage III melanoma, despite surgical resection and adjuvant systemic therapy, locoregional recurrences still occur. The randomized, phase III Trans-Tasman Radiation Oncology Group (TROG) 02.01 trial demonstrated that adjuv
Externí odkaz:
https://doaj.org/article/35448e0e51c54b988eb95ba45ce8d0d2
Autor:
Seda Kahraman, Enes Erul, Mustafa Seyyar, Ozge Gumusay, Ertugrul Bayram, Burcin Cakan Demirel, Omer Acar, Sercan Aksoy, Naziyet Kose Baytemur, Elif Sahin, Devrim Cabuk, Gul Basaran, Semra Paydas, Arzu Yaren, Deniz Can Guven, Atike Pinar Erdogan, Umut Demirci, Alper Yasar, İbrahim Vedat Bayoglu, Mutlu Hizal, Burcu Gulbagci, Nail Paksoy, Sena Ece Davarci, Funda Yilmaz, Ozlem Dogan, Sibel Oyucu Orhan, Erkan Kayikcioglu, Ali Aytac, Merve Keskinkilic, Eda Eylemer Mocan, Olcun Umit Unal, Esra Aydin, Hakan Yucel, Deniz Isik, Onder Eren, Basak Oyan Uluc, Melike Ozcelik, Ilhan Hacibekiroglu, Adnan Aydiner, Hacer Demir, Berna Oksuzoglu, Ebru Cilbir, Erdem Cubukcu, Bulent Cetin, Esin Oktay, Cihan Erol, Sadi Kerem Okutur, Nilgun Yildirim, Ali Alkan, Fatih Selcukbiricik, Asude Aksoy, Yusuf Karakas, Gulhan Ozkanli, Berna Bozkurt Duman, Dincer Aydin, Ozgecan Dulgar, Muhammed Muhiddin Er, Fatih Teker, Tugba Yavuzsen, Musa Baris Aykan, Ali Inal, Yakup Iriagac, Nurhan Onal Kalkan, Murat Keser, Teoman Sakalar, Serkan Menekse, Engin Kut, Burak Bilgin, Muge Karaoglanoglu, Veli Sunar, Ozlem Ozdemir, Nazim Serdar Turhal, Nuri Karadurmus, Bulent Yalcin, Mehmet Ali Nahit Sendur
Background: Ribociclib, palbociclib and abemaciclib are currently approved CDK4/6 inhibitors along with aromatase inhibitors as the first-line standard-of-care for patients with hormone receptor-positive, HER2-negative metastatic breast cancer. Metho
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::af4603b0dea982cdc71feb0666817cb5
https://avesis.deu.edu.tr/publication/details/6b4454d1-de76-4c63-9dab-2c0deccc7b07/oai
https://avesis.deu.edu.tr/publication/details/6b4454d1-de76-4c63-9dab-2c0deccc7b07/oai
Autor:
Prachi Bhave, Angela Hong, Serigne N Lo, Rebecca Johnson, Johanna Mangana, Douglas B Johnson, Ozgecan Dulgar, Zeynep Eroglu, Hui-Ling Yeoh, Andrew Haydon, Georg C Lodde, Elisabeth Livingstone, Adnan Khattak, Katharina Kähler, Axel Hausschild, Grant A McArthur, Alexander Maxwell Menzies, Georgina Long, Wei Wang, Matteo S Carlino
Publikováno v:
Journal for ImmunoTherapy of Cancer. 11:e006629
BackgroundIn patients with stage III melanoma, despite surgical resection and adjuvant systemic therapy, locoregional recurrences still occur. The randomized, phase III Trans-Tasman Radiation Oncology Group (TROG) 02.01 trial demonstrated that adjuva
Publikováno v:
American Journal of Clinical Dermatology. 22:1-10
About half of all cutaneous melanomas harbor activating mutations in the BRAF oncogene. Dependence on this pathway makes the tumors vulnerable to BRAF (and downstream MEK) inhibition, and three drug combinations are approved to target this vulnerabil
Publikováno v:
Revista espanola de medicina nuclear e imagen molecular.
Prediction of the pathologic response to neoadjuvant chemotherapy (NAC) in patients with locally advanced breast cancer is essential for optimal treatment strategy. The current approach of adjuvant or neoadjuvant treatment is based on the molecular s
Publikováno v:
Bosnian Journal of Basic Medical Sciences, Vol 18, Iss 4 (2018)
Aldehyde dehydrogenase 1 (ALDH1) has been identified as a marker of cancer stem cells in breast cancer (BC). Recent studies showed that ALDH1 expression is correlated with poor prognostic parameters and worse clinical outcome in BC. We evaluated ALDH
Autor:
Ezel Erşen, Buge Oz, Ahmet Emre Eskazan, Akif Turna, Nukhet Tuzuner, Ahu Senem Demiröz, Ozgecan Dulgar
Publikováno v:
Journal of Infection and Chemotherapy. 22:53-57
Gaucher disease (GD) is an autosomal recessive glycolipid storage disorder, due to deficiency of the lysosomal enzyme glucocerebrosidase, leading to accumulation of the substrate glucocerebroside in the cells of the macrophage-monocyte system. Patien
Autor:
İlkay Gültürk, Gülçin Şahingöz Erdal, Gülru Birce Sönmezoz, Mesut Yılmaz, Seher Yıldız Tacar, Aykut Özmen, Deniz Tataroğlu Özyükseler, Özgecan Dulgar, İbrahim Çil, Deniz Tural
Publikováno v:
İstanbul Medical Journal, Vol 23, Iss 4, Pp 269-274 (2022)
Introduction:For metastatic prostate cancer (PC), androgen deprivation therapy (ADT) is the primary treatment option. Most patients develop resistance, after an initial response to treatment. This study aimed to evaluate real-life data of first-line
Externí odkaz:
https://doaj.org/article/4fd073773cc34e1c9b30ce4d1b0e41c1